Tag Archive for: bispecific antibody
PT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxAPVO442: A Promising New Bispecific Antibody for Prostate Cancer Treatment
/0 Comments/in Preclinical Research/by MaxTags
abiraterone acetate ADT ai in healthcare alphafold androgen deprivation therapy antibody-drug conjugate apalutamide artificial intelligence bispecific antibody bone metastases CAN-2409 cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology personalized medicine prostate cancer PSA response PSMA radioligand therapy radiopharmaceuticals small molecule STEAP1 survival outcomes targeted therapy theranostics treatment resistance
Latest Posts
- RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy January 14, 2025
- Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer January 14, 2025
- Results from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer January 14, 2025
- Phase 3 Trial of BMS-986365 January 13, 2025